ProImmune Conference Videos | ProImmune
ProImmune Videos
Mastering Immunity 6

Dr. Valerie Quarmby
Genentech

"Host Cell Proteins and Immunogenicity"

Dr. Daron Forman
Bristol-Myers Squibb

"The use of immunogenicity risk assessment tools for lead optimization of biologics"

 

Dr. Erik Meyer
GlaxoSmithKline

"Therapeutic Immunogenicity: Target Interference and Cut Point Evaluation"

Dr. Jeremy Fry
ProImmune

"An integrated approach to managing immunogenicity risk and drug immune modulation"

Dr. Wojciech Jankowski
FDA

"Non-clinical Assessments of Immunogenicity"


 

 

Dr. Eric Zanelli
Déclion Holdings

"DP-C016, a phosphoTau vaccine for the treatment of tauopathies"

Dr. Nik Schwabe
ProImmune

 

"Epitope identification and clinical immune monitoring in immune oncology programmes"

Mr Govinda Sharma
British Columbia Cancer Agency

"Functional identification of CD8+ T cell epitopes by parallel interrogation of more than a million distinct peptide-coding sequences"

 

Dr. Scott McClain
Syngenta Crop Protection

 

"Bioinformatic screen and detection of immunologically relevant cross-reactive IgE-binding epitopes"

Mastering Immunity Europe 2017

Dr. Bernard Maillère
CEA, France

"Specificity and phenotype of pre-existing T cells against therapeutic proteins"

Dr. Menna Clatworthy
University of Cambridge, UK

"Immune complexes modulate immune highways and DC trafficking"


 

 

Prof. Farzin Farzaneh
King's College London, UK

"Therapeutic Cancer Vaccines"

Dr. Bartek Zuber
Swedish Orphan Biovitrum, Sweden

"Immunogenicity assessment for Affibody-Fc fusion therapeutics
"

Dr. Tim Hickling
Pfizer, USA

 

"Applying in vitro immunogenicity assays to predicts clinical immunogenicity"

Dr. Sophie Sibéril
UPMC, Paris, France

 

"Analysis of peripheral T cell compartments in high-grade Follicular Lymphoma patients treated with rituximab-based regimens"

 

Prof. Yu-Chan Chao
Academia Sinica, Taiwan

"Display of foreign surface antigens on baculovirus as pseudotyped viruses for immunological studies and applications"

 

 

Prof. Tim Elliott
University of Southampton, UK

"Applying mechanism based computational models to CTL epitope prediction"

Prof. Mark Exley
Agenus Inc., USA

"Phosphopeptide NeoAntigens for Tumor Immunity: Novel therapeutic options"

 
Prof. Christine Falk
Medizinische Hochschule Hannover, Germany

"Precision Medicine in Transplantation - immune monitoring for the discrimination of GVHD, rejection and CMV infection"

Prof. Miles Carroll
Public Health England, UK

 

"Understanding the immune response to EBOV during acute disease and in EVD survivors"

 
Mastering Immunity Europe 2016

Prof. Herman Waldmann
University of Oxford

"Short-term therapeutic intervention for the therapeutic harnessing of tolerance mechanisms"

Dr. Farnaz Fallah-Arani
UCB Pharma, UK

“Challenges to experimental design to test immunotherapeutic drugs to achieve clinically relevant results.”

 

 

Dr. Jeremy Fry
ProImmune Ltd., UK

“An integrated approach to managing immunogenicity risk and drug immune modulation.”

Dr. Bernd Schlereth
Covagen, Switzerland

“Special considerations in pharmacokinetic and immunogenicity assessment of bispecific antibody constructs”

 

Dr. Bernard Maillère
CEA, France

“Comprehensive analysis of pre-existing T cells specific to therapeutic proteins in healthy donors”

Prof. David Wraith
University of Bristol

“Antigen-specific tolerance induction: allergy, autoimmunity and anti-drug antibodies”

Dr. Peter Adler Wurtzen
ALK-Abelló, Denmark

“Immunological biomarkers in Allergy Immunotherapy”

Prof. Paul Moss
University of Birmingham

“Direct visualisation of antigen-specific CD4+ T cells: insights from HLA class II tetramers”

 

 

 

Prof. Ada Kruisbeek
DCPrime, The Netherlands

“Developing off-the-shelf dendritic cell based vaccines: pre-clinical and clinical observations”

   

Dr. Wei Xue
Roche Innovation Center Zurich, Switzerland

“Combination immunotherapy and vaccines in cancer”

 

 

 

 

 

Mastering Immunity 5 (2015)

Dr. Ethan Shevach
NIAID, NIH

"Tregs -ready for the clinic"

Dr. Keith Knutson
Mayo Clinic, Jacksonville

“Vaccines for Prevention of Breast Cancer”

Prof. Jean Rommelaere
DKFZ, Germany

“Use of oncolytic parvoviruses in the treatment of malignant gliomas: a viro-immunotherapeutic approach”

 

 

Dr. Jeremy Fry
ProImmune

“An integrated approach to managing immunogenicity risk and drug immune modulation”

Dr. Xiaoying Chen
Pfizer, Inc.

“A Systems Pharmacology Approach to Immunogenicity – A multi-scale, Mechanistic Mathematical Model and Its Applications”

 

Prof. Armagan Kocer
University of Groningen

“Ion channel decorated liposomes: therapeutic potential and immunogenicity”

Prof. David Wraith
University of Bristol

“Switching off immunity: the mechanism of antigen-specific immunotherapy”

Prof. Julio Delgado
University of Utah

“Assessment of TNF-alpha antagonists and Anti-Drug Antibodies in the Clinical Laboratory”

Dr. Gene Olinger
NIAID, NIH

“Development of a monoclonal antibody cocktail for Ebola virus therapy: convergence of plants, mice, and humans”

 

 

   

Prof. Lawrence Steinman
Stanford University

“Vaccines, adjuvants, and autoimmunity”

 

 

 

 

 

 

Mastering Immunogenicity 4 (2014)

Prof. Herman Waldmann
University of Oxford

"Tolerance can be induced in the adult immune system"

Prof. Arlene Sharpe
Harvard University

“T Cell Coinhibitory Pathways and Cancer Immunotherapy: Roles of the PD-1 pathway in controlling tolerance and tumor immunity”

 

Dr. Timothy Hickling
Pfizer, Inc.

“Contribution of ex vivo assays to immunogenicity risk assessment”

Dr. Sabine Zollner
CSL Behring

 

“Preclinical characteristics of rVIII-SingleChain, a novel recombinant single-chain FVIII under clinical development at CSL Behring”

Dr. Nades Palaniya
The Hospital for Sick Children, Toronto

“Targeting innate immune collectins and neutrophil extracellular traps (NETs) to regulate inflammatory diseases”

Dr. Joleen White
Biogen IDEC

 

“Evaluation of Peginterferon Beta-1a and Interferon Beta-1a Pharmacokinetics, Pharmacodynamics, and Immunogenicity in Multiple Sclerosis”

 

Dr. Jeremy Fry
ProImmune

 

“Tools and Technologies for Immunogenicity Risk Management”

Dr. Bruce Hall
University of New South Wales

“Antigen specific CD4+CD25+Foxp3+Treg generated from natural Treg (nTreg)”

 

 

Dr. Amy Loercher
GSK

 

“ABIRISK Developments and Challenges: Perspectives from Year 2”

   

Dr. Susan Kirshner
FDA

“Therapeutic Proteins: Routes of Exposure and the risk of immunogenicity”

 

 

 

 

 

Mastering Immunogenicity 3 (2013)

Prof. David Wraith
University of Bristol

"Dealing with Unwanted Immunogenicity: The Design and Development of Tolerogenic T Cell Epitopes"

 

 

Dr. Florian Deisenhammer
Innsbruck

“Drug Immunogenicity: Lessons Learnt from Interferon-beta”

Dr. Beth Chang
Amunix

“XTEN in Blood Factor Engineering”

Dr. William Sanderson
University College London

“Phenotypic Structure of B Cell Subsets as a Tool for the Investigation for Immunogenicity”

Dr. Michael Cancro
University of Pennsylvania

“B Cell Selection and Survival: First Order Consideration for Immunogenicity”

 

 

 

Dr. Larry Kauver
Trellis

“Antibody Repertoire Monitoring: Application to Anti-Drug Antibodies”

Dr. Jeremy Fry
ProImmune

“Mastering Immunogenicity: Tools and Technologies”

Dr. Samuel Pine
Allergan

“Immunologic Endpoints for Guiding Biologic Drug Development”

Dr. Caroline Barelle
University of Aberdeen

“Shark VNAR Domains: Immunogenicity Determination in the Early Stages of Development Aids Candidate Selection for "First-Man" Studies”

 

   

Dr. Federico Mingozzi
University Pierre et Marie Curie

“Assessing and Modulating Immune Responses to AVV Vectors in Humans”

 

 

 

 

 

Mastering Immunogenicity 2 (2012)

Dr. Manoj Rajadhyaksha
Regeneron

"Working towards building a “Value Added Proposition” for Immunogenicity Prediction and Risk Management"

Prof. Bonnie Rup
Pfizer

“Understanding the problem of unwanted immunogenicity risk in biotherapeutic discovery and development: advances, gaps, opportunities”

Dr. Jeremy Fry
ProImmune

“Tools and technologies for comprehensive immunogenicity risk management”

 

Dr. Nikolai Schwabe
ProImmune

“Mastering Immunity: ProStorm™ Cytokine Release Assay”

Dr. Bob DuBridge
Full Spectrum Genetics

“MapEng™ A Powerful, New Tool in the Engineering of Biobetter Therapeutics”

 

 

 

 

Best Practice Immunogenicity Risk Management (2012)

Dr. Tim Hikling
Pfizer

 

"Immunogenicity of biotherapeutics: Why do we care and where do we stand?"

Dr. Robin Thorpe
NIBSC Health Protection Agency

“CHMP Guidance on Unwanted Immunogencity: Best Practice Iummunogenicity Risk Management: Oxford 2012”

 

Dr. Katharina Steinitz
Baxter Innovations GmbH

 

“Identification of promiscuous FVIII-specific CD4+ T-cell epitopes in a humanized mouse model for hemophilia A”

 

Dr. Heather Hinton
Roche

“Pre-Clinical Risk Assesment Using Innovative Technologies”

Dr. David Ulaeto
DSTL

“Therapeutic potential of a humanised antibody for the treatment of Venezuelan Equine Encephalitis Virus”